Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the first quarter of 2024.
- First-quarter revenue was $1.62 billion, which is up 5% on a reported basis and 7% at constant currency
- Women’s Health revenue increased by 11% and Biosimilars revenue climbed by 46%
- Meanwhile, Established Brands revenue was flat on an as-reported basis during the quarter
- Reported earnings per share and adjusted earnings per share were $0.78 and $1.22, respectively, during the three months
- Net income came in at $201 million in the March quarter and adjusted EBITDA was $538 million
- Gross margin was 59.0% on a reported basis and 62.1% on an adjusted basis in the first quarter
- Adjusted EBITDA margin dropped to 33.2% in the first quarter from 33.7% last year
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Accenture (ACN) likely to extend revenue growth in Q4 2025 despite challenges
Accenture (NYSE: ACN) has consistently delivered quarterly revenue growth across its operating segments this year, pushing both top-line and earnings above analysts' estimates. That momentum is expected to continue when
Darden Restaurants (DRI): A look at the restaurant chain’s performance in Q1 2026
Shares of Darden Restaurants, Inc. (NYSE: DRI) were down over 2% on Friday. The stock has dropped 17% year-to-date. The restaurant operator delivered sales and earnings growth for the first
Intuit (INTU) reaffirms first-quarter and fiscal 2026 financial guidance
Financial technology company Intuit Inc. (NASDAQ: INTU) has published its financial outlook, reaffirming first-quarter and full-year guidance. For the first quarter of fiscal 2026, the company continues to expect revenue
